

## **Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference**

CUPERTINO, Calif., Sept. 26, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.

### **Company Webcast**

The webcasted presentation will take place at 3:30 p.m. ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference registration at <https://app.webinar.net/Xokw4go4qvO>. The webcast can also be accessed by visiting the conference home page at <https://lythampartners.com/fall2024> or on the Company’s website at <https://revivapharma.com>. The webcast will also be available for replay following the event.

### **1×1 Meetings**

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at <https://lythampartners.com/fall2024invreg>.

### **About Reviva**

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

### **Corporate Contact:**

Reviva Pharmaceuticals Holdings, Inc.  
Laxminarayan Bhat, PhD  
[www.revivapharma.com](http://www.revivapharma.com)

**Investor Relations Contact:**

LifeSci Advisors, LLC

Bruce Mackle

[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)

